Over the past 30 years, the genetic sequencing revolution has transformed how ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) are diagnosed, and it is set to change how they are treated.
Professor Matthew Harms explains that almost 20 genes have now been reported to cause an FTD-like phenotype and close to 50 in ALS. Genetic testing yields an answer in about 20% of people with FTD and 15% with ALS, including around 1 in 10 people with no family history of either disease. Beyond confirming the diagnosis and informing families about future risk, testing is becoming a treatment concept. One therapy is already approved for SOD1-related ALS, and gene-targeted therapies that silence or boost gene expression are in clinical trials for both disorders.